Navigation Links
BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
Date:4/26/2008

to 96 weeks. Treatment response in this study is defined as HBeAg seroconversion and viral load less than 10^4 copies/mL for 24 weeks, with undetectable viral load at the end of the 24-week period.

Indication and Important Safety Information About BARACLUDE(R) (entecavir) 0.5 mg/1 mg Tablets

BARACLUDE(R) (entecavir) is a prescription medicine used for chronic infection with hepatitis B virus (HBV) in adults where the virus is multiplying and damaging the liver. BARACLUDE does not cure HBV or stop the spread of HBV to others. People should not take BARACLUDE if they are allergic to it or any of its ingredients. BARACLUDE has not been studied in children and is not recommended for anyone less than 16 years of age.

People taking BARACLUDE(R) (entecavir) should tell their healthcare provider right away if they feel very weak or tired, have unusual muscle pain, have trouble breathing, have stomach pain with nausea and vomiting, feel cold -- especially in their arms and legs, feel dizzy or lightheaded, or have a fast or irregular heartbeat, as they may be signs of a serious condition called lactic acidosis (buildup of an acid in the blood). Lactic acidosis is a medical emergency and must be treated in the hospital. Some people who have taken medicines like BARACLUDE have developed serious liver problems called hepatotoxicity. This may occur with liver enlargement (hepatomegaly) and fat in the liver (steatosis).

People should call their healthcare provider right away if they get any of the following signs of liver problems: yellowing (jaundice) of the skin or the white part of the eyes, darkening of the urine, lightening in the color of bowel movements (stools), not feeling like eating food for several days or longer, feeling sick to the stomach (nausea), or having lower stomach pain. Lactic acidosis and hepatotoxicity have happened in some people taking medicines like BARACLUDE.

For people taking BARACLUDE who have or get HIV (the virus
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Many Heart Attack Patients Dont Get Best Emergency Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- The global ... of products, methods, applications, end users, and geographies. ... in the microbial identification market. This favorable growth ... (per test) and the time required for microbial ... technological advancements. Furthermore, genotypic methods have high applications ...
(Date:7/29/2014)... BASKING RIDGE, N.J. , July 29, 2014 /PRNewswire/ ... a biopharmaceutical company focused on the Phase 3 clinical ... first-in-class, actively controllable antithrombotic drug system, today announced that ... webcast on Tuesday, Aug. 12, 2014, at 8:30 a.m. ... and corporate highlights. Interested participants and investors ...
(Date:7/29/2014)...  Landauer, Inc. (NYSE: LDR ), a ... monitoring, outsourced medical physics services and high quality medical ... third quarter 2014 after the market close on Monday, ... host a conference call for investors on Tuesday, August ... Eastern Time). Investors may access the live call by ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2
... Reported in 4Q 2007 -, LA JOLLA, ... TPTX ) today announced that it has completed,enrollment ... for the treatment,of acute migraine headache. Tezampanel is ... non-vascular and non-serotonergic,approach to the management of pain ...
... 3 trial of Genasense(R) seeks to confirm benefit in melanoma -- ... Company regains compliance for NASDAQ Global Markets listing; Genta common stock ... program for Genasense will continue ... during Phase 3 trial ...
Cached Medicine Technology:TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache 2TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache 3TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache 4Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 2Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 3Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 4Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 5Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 6Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 7Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights 8
(Date:7/30/2014)... An interesting fact about motorcyclists was ... enthusiasts congregate, BikerKiss.com . The number and ratio ... by BikerKiss indicate that women motorcycle riders have been ... , Members on BikerKiss are mostly single bikers ... other European countries who are there looking for friendship ...
(Date:7/30/2014)... July 30, 2014 My Clients ... over 80 different electronic therapy note templates. Healthcare ... and other computing devices all while meeting the ... or electronic medial records (EMR) consist of psychological ... other essential categories. SOAP and DAP note ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Nuanced Media, a ... announce the release of the Medical Web Design Trends of ... of research done across multiple agencies and the medical web ... are constantly changing as the industry grows. Therefore it is ... of ideas that consumers enjoy most. New trends are defined ...
(Date:7/29/2014)... Phytceramides are a natural anti-aging tool for improving skin, ... , Today is the last day to nab a free download ... The book is also sold in hard copy. , "I am ... Phytoceramides were so new and very unknown in the U.S. ... says Kathy Heshelow, founder of Sublime Beauty®. "It is an easy ...
(Date:7/29/2014)... Colorado (PRWEB) July 29, 2014 Daily ... as well as all other disturbing symptoms that hemorrhoids ... Hayden, a researcher and natural medicine expert. , ... will lead to the elimination of symptoms such as ... , Learn more about the H Miracle by ...
Breaking Medicine News(10 mins):Health News:Single Women Motorcycle Riders In Rapid Increase 2Health News:My Clients Plus Announces Over 80 Online Therapy Notes to Help Healthcare Providers Go Paperless 2Health News:Nuanced Media Releases "Medical Web Design Trends of 2014" Article 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 3Health News:H Miracle Review Exposes Natural Method to Cure Hemorrhoids 2
... million new infections //reported in 2006, with sub-Saharan Africa alone ... UNAIDS report. ,The UNAIDS/WHO 2006 AIDS Epidemic Update released ... living with HIV. Of these, about 8.6 million are in ... the past year. ,India is estimated to have ...
... separated in childhood could face an increased risk of ... study. ,The traditional view has been that psychosis ... and most psychiatrists have believed that social factors cannot ... ,The new study by the Institute of Psychiatry here ...
... doctor who mistakenly gave her the all clear after reading ... consultant surgeon John Philip was working in a private clinic ... ,The woman she was healthy after routine checks in ... X-rays, the General Medical Council (GMC) hearing was told. ...
... to help people caring for family members with dementia//, ... to a multi-site study co-authored by a University of ... 21 issue of Annals of Internal Medicine, indicate the ... improve the quality of life for the caregiver. ...
... priest, well-known for his care and protection of Aids orphans//in ... ,He was the MD, founder and medical director of ... ,Fr Joachim Omolo Ouko AJ of People for Peace in ... ,He said, "Father D'Agostino is not only remembered for his ...
... bacteria.It is usually found in eggs infected by foecal germs. ... found more often in chicken meat. Tests conducted during the ... enteritidis on chicken meat., ,Salmonella is reported to cause ... annual death toll of about 600 in the US. ...
Cached Medicine News:Health News:More then Four Million New HIV Infections in 2006: UNAIDS 2Health News:Blundering Doctor Destroys Breast X-ray 2Health News:Dementia Care Intervention Eases Burden for Families 2Health News:Dementia Care Intervention Eases Burden for Families 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: